{"schema_version":"secwatch.filing_event.v1","accession":"0000921299-25-000007","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.708626+00:00","generated_at":"2026-05-17T08:11:05.187412+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FibroGen completes sale of China business to AstraZeneca for ~$220M; repays $81M term loan","bullets":["Sale price ~$220M: $85M enterprise value plus ~$135M net cash held in China.","Net cash received $210.4M; transaction costs $7.7M; net assets sold $138.9M.","Pro forma cash and equivalents rise to $145M from $23M; pro forma deficit narrows to $1.684B.","Repaid $80.9M to MSTV, including $73.7M term loan balance and $6.8M loss on debt extinguishment.","Released $142.9M deferred revenue related to China single performance obligation."],"urls":{"canonical":"https://secwatch.observer/filing/0000921299-25-000007","json":"https://secwatch.observer/filing/0000921299-25-000007.json","markdown":"https://secwatch.observer/filing/0000921299-25-000007.md","text":"https://secwatch.observer/filing/0000921299-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/0000921299-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/fgen-20250829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:11:05.187412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85be62e6adbd4c3b02ef18be06142320383a5ecb","claim":"KYNTRA BIO, INC. completed a disposition involving AstraZeneca Treasury Limited for approximately $220 million (closed 2025-08-29).","evidence_excerpt":"sold all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, for approximately $220 million","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000092129925000007/0000921299-25-000007-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"AstraZeneca Treasury Limited"},{"label":"Consideration","value":"approximately $220 million"},{"label":"Closing","value":"2025-08-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}